Buy Pemazyre from insulinhub. Product of Europe.
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25
1105 BP Amsterdam
Netherlands
Information about Pemazyre (Pemigatinib)
Pemazyre is a prescription medication that contains pemigatinib as its active ingredient. It is a targeted therapy, specifically a selective fibroblast growth factor receptor (FGFR) inhibitor. Pemigatinib works by blocking certain signals that drive the growth of cancer cells. It is primarily used in the treatment of advanced or metastatic cancer types that involve abnormal FGFR pathway activity.
Product Highlights
- Pemazyre is used for the treatment of adults with previously treated, locally advanced, or metastatic intrahepatic cholangiocarcinoma (iCCA) that has FGFR2 fusion or mutation as determined by an FDA-approved test.
Key Ingredient
Key Benefits
- Focuses on the FGFR pathway, which plays a significant role in tumor cell proliferation in cancers with FGFR genetic alterations.
- Easy-to-take tablet formulation, making it convenient for long-term use.
- Demonstrated clinical benefit for patients with FGFR2 fusions or mutations, especially in cholangiocarcinoma where these mutations are prevalent.
Direction of Use
- Pemazyre is typically taken orally, once daily, with or without food.
- The recommended starting dose is 9 mg once a day, with dose modifications depending on individual tolerance and side effects.
- In some cases, the dose may be reduced to 4 mg based on the patient's response and adverse events.
- Treatment is usually continued until disease progression or unacceptable toxicity occurs.
Safety Concerns
- Can cause retinal problems, including retinal detachment and retinal pigment epithelial changes. Regular eye exams are necessary.
- Elevated phosphate levels in the blood are common and require monitoring.
- There is a risk of TLS, especially during the first few weeks of treatment, which requires close monitoring.
- Liver function should be monitored, as Pemazyre can lead to liver enzyme changes.
- Diarrhea, nausea, and vomiting are common adverse effects.
Avoid Pemazyre (Pemigatinib) If
- If you have had an allergic reaction to Pemigatinib or any component of the medication.
- If you have a history of severe retinal disorders or have ongoing eye issues that could worsen with treatment.
- If you have significant liver disease or impaired liver function, Pemazyre may not be appropriate.
- Pemazyre should be avoided during pregnancy, as it may harm a developing fetus. It is also not recommended during breastfeeding due to potential risks to the infant.
